Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

British Journal of Pharmacology

Volumn 125, Issue 7, 1998, Pages 1463-1470

  Tahara, Atsuo ^a   Saito, Masayuki ^a   Sugimoto, Toru ^a   Tomura, Yuichi ^a   Wada, Koh Ichi ^a   Kusayama, Toshiyuki ^a   Tsukada, Junko ^a   Ishii, Noe ^a   Yatsu, Takeyuki ^a   Uchida, Wataru ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Human vasopressin receptors; SR 121463A; SR 49059; YM087

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CALCIUM ION; CONIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; RECEPTOR SUBTYPE; RELCOVAPTAN; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CHO CELL; DISSOCIATION CONSTANT; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; SCATCHARD PLOT; SIGNAL TRANSDUCTION;

EID: 7844251895     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702220     Document Type: Article

References (35)

1. BIRNBAUMER, M., SEIBOLD, A. GILBERT, S., ISHIDO, M., BARBERIS, C., ANTARAMIAN, A., BRABET, P. & ROSENTHAL, W. (1992). Molecular cloning of the receptor for human antidiuretic hormone. Nature, 357, 333-335.
2. BUTLEN, D., GUILLON, G., RAJERISON, R.M., JARD, S., SAWYER, W.H. & MANNING, M. (1978). Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions. Mol. Pharmacol., 14, 1006-1017.
3. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
4. FUJJISAWA, G., ISHIKAWA, S., TSUBOI, Y., OKADA, K & SAITO, T. (1993). Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int., 44, 19-23.
5. lb vasopressin receptor in rat adrenal medulla. Endocrinology. 137, 3906-3914.
6. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
7. GUILLON, G., TRUEBA, M., JOUBERT, D., GRAZZINI, E., CHOUINARD, L., COTE, M., PAYET, M.D., MANZONI, O., BARBERIS, C., ROBERT, M. & GALLO-PAYET, N. (1995). Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiolensin-II effect. Endocrinology, 136, 1285-1295.
8. HOWL, J., ISMAIL, T., STRAIN, A.J., KIRK, C.J., ANDERSON, D. & WHEATLEY, M. (1991). Characterization of the human liver vasopressin receptor. Biochem. J., 276, 189-195.
9. 1 renal epithelial cells at physiological temperature. EMBO J., 8, 2481-2488.
10. JARD, S., GAILLARD, R.C., GUILLON, G., MARIE, J., SCHOENENBERG, P. & MULLER, A.F. (1986). Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol. Pharmacol., 30, 171-177.
11. 1a type. Am. J. Physiol., 253, F41-F49.
12. LASZLO, F.A., LASZLO, F. JR. & DE WIED, D. (1991). Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev., 43, 73-108.
13. 1b receptors. Am. J. Physiol., 269, E1095-E1100.
14. MICHELL, R.H., KIRK, C.J. & BILLAH, M.M. (1979). Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans., 7, 861-865.
15. MIZUSHIMA, S. & NAGATA, S. (1990). pEF-BOS, a powerful mammalian expression vector. Nucleic. Acids. Res., 18, 5322.
16. NAITOH, M., SUZUKI, H., MURAKAMI, M., MATSUMOTO, A., ARAKAWA, K., ICHIHARA, A., NAKAMOTO, H., OKA, K., YAMAMURA, Y. & SARUTA, T. (1994). Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol., 267, H2245-H2254.
17. NISHIKIMI, T., KAWANO, Y., SAITO, Y. & MATSUOKA, H. (1996). Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J. Cardiovasc. Pharmacol., 27, 275-282.
18. 1 receptor of rat. rhesus and human tissues. Life Sci., 50, 1953-1958.
19. 2 selective ligands. Endocrinology, 126, 1478-1484.
20. 1a antagonist, on human vascular smooth muscle cells. Am. J. Physiol., 268, H404-H410.
21. 2 receptor antagonist. J. Clin. Invest., 98, 2729-2738.
22. 1a receptors. J. Clin, Invest., 92, 224-231.
23. 1b vasopressin receptor. J. Biol. Chem., 269, 27088-27092.
24. TAHARA, A., TOMURA, Y., WADA, K., KUSAYAMA, T., TSUKADA, J., ISHII, N., TAKEYUKI, Y., UCHIDA, W. & TANAKA, A. (1997a). Effect of YMO87. a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J. Cardiovasc. Pharmacol., 30, 759-766.
25. 2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther., 282, 301-308.
26. TAHARA, A., TOMURA, Y., WADA, K., KUSAYAMA, T., TSUKADA, J., ISHII, N., TAKEYUKI, Y., UCHIDA, W. & TANAKA, A. (1998). Effect of YM087, a potent nonpeptidc vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res., in press.
27. TAKEDA, T., KUNO, T., SHUNTOH, H. & TANAKA, C. (1989). A rapid filtration assay for cAMP. J. Biochem., 105, 327-329.
28. TENCE, M., GUILLON, G., BOTTARI, S. & JARD, S (1990). Labeling of vasopressin and oxytocin receptors from the human uterus. Eur. J. Pharmacol., 191, 427-436.
29. THIBONNIER, M. (1992). Signal transduction of V1-vascular vasopressin receptors. Regul. Pep., 38, 1-11.
30. 1a, vasopressin receptor., J. Biol. Chem., 269, 3304-3310.
31. THIBONNIER, M. & ROBERTS, J.M. (1985). Characterisation of human platelet vasopressin receptors. J. Clin. Invest., 76, 1857-1864.
32. WEINGARTNER, H., COLD, P., BALLENGER, J.C., SMALLBERG, S.A., SUMMERS, R., RUBINOW, D.R., POST, R.M. & GOODWIN, F.K. (1981). Effects of vasopressin on human memory functions. Science. 211, 601-603.
33. YAMAMURA, Y., OGAWA, H., CHIHARA, T., KONDO, K., ONOGAWA, T., NAKAMURA, S., MORI, T., TOMINAGA, M. & YABUUCHI, Y. (1991). OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science, 252, 572-574.
34. 2 receptor antagonist. Br. J. Pharmacol., 105, 787-791.
35. 2 receptor antagonist, in dogs. Eur., J. Pharmacol., 321, 225-230.